Prosecution Insights
Last updated: November 08, 2026

Mesoblast Inc.

Technology area: Biotechnology & Pharmaceuticals

3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Analysis

Mesoblast Inc. is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 3 pending office actions are assigned to 3 distinct examiners, which means each examiner is handling exactly one of the company's pending matters. The prosecution is further spread across 3 distinct art units, indicating that the company's biotechnological innovations are technically diverse and fall into several different classification categories.

ALLISON M FOX is identified as the busiest examiner for this portfolio, currently overseeing 1 pending office action. Since there are 3 pending office actions and 3 distinct examiners, the workload is evenly distributed, with no single examiner having more influence than the others. The fact that 3 distinct art units are involved for 3 pending office actions suggests that each application is being reviewed in a unique administrative environment.

For the practitioner, this distribution means that there is no overlap in the personnel or the departments reviewing the company's current filings. Each of the 3 pending office actions must be prosecuted according to the specific tendencies of a different examiner and the norms of a different art unit. ALLISON M FOX, as one of the 3 distinct examiners, represents just one part of a fragmented prosecution landscape that requires a highly individualized approach for each application.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

3
Total Pending OAs
1
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
0
Due this month
1
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (33%)
1
Easy (33%)
1
Unknown (33%)

Rejection Statute Mix

BucketCases
§112 only1 (33%)
Double-patenting + other1 (33%)
No statute on record1 (33%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

30 h
Manual time on pending OAs
6 h
Time saved (low, 20%)
10 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
FOX, ALLISON M 1 71.0% +35.7%
VIVLEMORE, TRACY ANN 1 72.9% +6.6%
WANG, CHANG YU 1 33.3% +53.8%

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18192398 METHOD OF TREATING GRAFT VERSUS HOT DISEASE FOX, ALLISON M —
17177065 METHODS OF TREATING OR PREVENTING NEUROLOGICAL DISEASES WANG, CHANG YU —

Top Art Units

Art UnitApps
1633 1
1638 1
1675 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18192398 METHOD OF TREATING GRAFT VERSUS HOT DISEASE FOX, ALLISON M 1633 §112DP Final Rejection — Pending Mar 29, 2023
17901424 TREATMENT OF EXCESSIVE NEOVASCULARIZATION VIVLEMORE, TRACY ANN 1638 Other Final Rejection 55d Pending Sep 01, 2022
17177065 METHODS OF TREATING OR PREVENTING NEUROLOGICAL DISEASES WANG, CHANG YU 1675 §112 Non-Final OA — Pending Feb 16, 2021

Managing Mesoblast Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Mesoblast Inc. have?

Mesoblast Inc. has 3 pending office actions as of November 2026, spread across 3 art units and 3 examiners.

Which USPTO examiner handles the most Mesoblast Inc. applications?

Allison M Fox has the most, with 1 of Mesoblast Inc.'s pending office actions.

What technology area are Mesoblast Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month